Medical technology company Hologic (NASDAQ: HOLX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 1.2% year on year to $1.02 billion. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.

Is now the time to buy HOLX? Find out in our full research report (it’s free).

StockStory’s Take

Hologic delivered a solid second quarter, surpassing Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this outperformance to improved commercial execution in the Breast Health segment, particularly in imaging and interventional sales, as well as ongoing progress in diagnostics and surgical divisions. CEO Stephen MacMillan emphasized that “the operative word for Hologic in the third quarter was progress,” pointing to a rebound in previously challenged business areas and the successful integration of recent acquisitions, such as Endomag. The company also highlighted operational discipline, including expense control and tariff mitigation, as contributors to the positive results.

Looking ahead, Hologic’s updated guidance is shaped by confidence in accelerating growth from its core businesses and new product rollouts. Management expects the Breast Health division to return to top-line growth, supported by upgraded commercial strategies and new artificial intelligence offerings. CFO Karleen Oberton noted, “We expect mid-single-digit revenue growth and high single-digit EPS growth in the fourth quarter,” underpinned by the ongoing expansion of diagnostics, rising international demand for surgical products, and continued operational efficiency. The company remains focused on launching its Envision platform and capitalizing on growth opportunities in both established and emerging markets.

Key Insights from Management’s Remarks

Management credited the quarter’s performance to a rebound in Breast Health, solid diagnostics demand, and the early benefits of product and sales force changes.

• Breast Health recovery underway: Sequential improvement in 3D gantry shipments and early wins from a new end-of-life replacement strategy helped stabilize the Breast Health business, with management confident about continued momentum into the next quarter.
• Diagnostics resilience: Despite headwinds from funding cuts in Africa and a challenging China environment, the diagnostics division benefited from strong U.S. molecular testing and rising utilization of the Panther Fusion platform, which enables laboratories to consolidate more tests on a single automated system.
• Product innovation focus: Hologic launched the Genius AI Detection PRO, a cloud-based artificial intelligence tool for radiologists, which management views as a differentiator for breast imaging accuracy and efficiency. The company also highlighted recent clinical evidence supporting the benefits of its high-resolution 3D mammography.
• Endomag acquisition drives growth: The Endomag breast surgery products, including Magseed and Magtrace, contributed nearly $20 million in quarterly revenue and are expected to accelerate organic growth as their integration is completed.
• Tariff mitigation success: Through supply chain and procurement adjustments, management expects to cut tariff-related expenses by about half, reducing gross margin headwinds compared to initial estimates.

Drivers of Future Performance

Hologic’s outlook is driven by a combination of strengthening core businesses, new product launches, and ongoing cost management, tempered by international headwinds and product mix shifts.

• Breast Health turnaround: Management anticipates continued sequential growth in 3D gantry placements and the ramp-up of its end-of-life replacement strategy, with the launch of the Envision platform expected to further drive momentum in late 2026 and beyond.
• Diagnostics and molecular growth: The diagnostics division is expected to contribute steadily, with Panther Fusion menu expansion and increased U.S. molecular test adoption, though management cautioned that headwinds from China and HIV testing in Africa will persist through the first half of next year.
• Margin management amid tariffs: While tariff expenses remain a headwind, ongoing mitigation efforts and a favorable product mix are expected to maintain operating margins in line with current levels, even as discontinued products like Fluoroscan are phased out and new product introductions ramp up.

Catalysts in Upcoming Quarters

In upcoming quarters, StockStory analysts will be monitoring (1) execution of the Breast Health rebound, particularly the success of the end-of-life gantry replacement strategy and the Envision platform rollout; (2) the pace of molecular diagnostics adoption and menu expansion on Panther Fusion; and (3) the company’s ability to further mitigate tariff-related margin pressures. Sustained performance in international surgical markets and continued integration of recent acquisitions will also be closely tracked.

Hologic currently trades at $68.24, up from $64.96 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.